Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novartis AG (GB:0QLR)
LSE:0QLR
Novartis AG (0QLR) Share Price & Analysis
9 Followers
0QLR Stock Chart & Stats
Day’s RangeCHF0 - CHF0
52-Week RangeCHF77.09 - CHF97.53
Previous CloseCHF97.09
Volume78.75K
Average Volume (3M)550.09K
Market Cap
CHF191.36B
Enterprise ValueCHF196.70B
Total Cash (Recent Filing)$14.43B
Total Debt (Recent Filing)$20.26B
Price to Earnings (P/E)14.8
Beta0.46
Next Earnings
Jul 18, 2024EPS Estimate
CHF1.67Last Dividend Ex-Date
Mar 07, 2024Dividend Yield3.39%
Share Statistics
EPS (TTM)6.57
Shares Outstanding2,044,033,986
10 Day Avg. Volume143,462
30 Day Avg. Volume550,089
Standard Deviation0.05
R-Squared0.08
Alpha-0.00213
Financial Highlights & Ratios
Price to Book (P/B)-3.29
Price to Sales (P/S)3.71
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.59
Enterprise Value/Gross Profit5.75
Enterprise Value/Ebitda23.97
Forecast
1Y Price Target
CHF100.89Price Target Upside3.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNovartis had an extremely strong 1Q and reported well above expectations with 11% and 22% growth for sales and core OpInc respectively.
Guidance UpgradeNovartis raised its FY guidance both for sales and core OpInc growth, indicating strong performance and potential for further growth.
Pipeline And ApprovalsNovartis released detailed PIII data for four pipeline assets with peak sales potential of $9bn, supporting pipeline progress and growth potential post 2028.
Bears Say
Market ChallengesHigh unmet need in IgAN but increasingly crowded market could pose challenges.
Pricing StrategyIptacopan's premium pricing and potential position as a later line therapy could limit its market penetration to approximately 5% of patients.
Product PerformanceOncology products were weaker in general, with Promacta, Pluvicto, and Kisqali showing significant underperformance against expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
11.91% Mutual Funds
8.62% Other Institutional Investors
79.47% Public Companies and
Individual Investors
0QLR FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest share price was CHF77.09 and its highest was CHF97.53 in the past 12 months.
What is Novartis AG’s market cap?
Currently, no data Available
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Jul 18, 2024 which is in 11 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Apr 23, 2024. The company reported CHF1.626 earnings per share for the quarter, beating the consensus estimate of CHF1.516 by CHF0.11.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Undervalued.
Does Novartis AG pay dividends?
Novartis AG pays a Annually dividend of CHF3.3 which represents an annual dividend yield of 3.39%. See more information on Novartis AG dividends here
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is CHF1.67.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,189,930,400 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of CHF1.626 in its last earnings report, beating expectations of CHF1.516. Following the earnings report the stock price went up 3.377%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in GB:0QLR
---
Novartis AG Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
0QLR Stock 12 Month Forecast
Average Price Target
CHF100.89
▲(3.92% Upside)
Technical Analysis
Best Analysts Covering 0QLR
1 Year
1 Year Success Rate
33/41 ratings generated profit
1 Year Average Return
+6.95%
reiterated a buy rating 6 days ago
Copying Peter Welford's trades and holding each position for 1 Year would result in 80.49% of your transactions generating a profit, with an average return of +6.95% per trade.
---